RVMD Q2 2020 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$19B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-18.4% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$28M-279.1% margin

Net Income

-$27M-271.5% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-13.2%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$454M

Total Liabilities

$93M

Stockholders' Equity

$360M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$12M	-18.4%
Gross Profit	$10M	$12M	-18.4%
Operating Income	-$28M	-$11M	-165.0%
Net Income	-$27M	-$10M	-168.9%

Revenue Segments

Collaboration Revenue Related Party

$10M100%